These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
300 related articles for article (PubMed ID: 24418414)
1. Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer. Thangapazham R; Saenz F; Katta S; Mohamed AA; Tan SH; Petrovics G; Srivastava S; Dobi A BMC Cancer; 2014 Jan; 14():16. PubMed ID: 24418414 [TBL] [Abstract][Full Text] [Related]
2. Genetic interaction between Tmprss2-ERG gene fusion and Nkx3.1-loss does not enhance prostate tumorigenesis in mouse models. Linn DE; Bronson RT; Li Z PLoS One; 2015; 10(3):e0120628. PubMed ID: 25780911 [TBL] [Abstract][Full Text] [Related]
3. NKX3.1 Suppresses TMPRSS2-ERG Gene Rearrangement and Mediates Repair of Androgen Receptor-Induced DNA Damage. Bowen C; Zheng T; Gelmann EP Cancer Res; 2015 Jul; 75(13):2686-98. PubMed ID: 25977336 [TBL] [Abstract][Full Text] [Related]
4. Micro-RNA-204 Participates in TMPRSS2/ERG Regulation and Androgen Receptor Reprogramming in Prostate Cancer. Todorova K; Metodiev MV; Metodieva G; Mincheff M; Fernández N; Hayrabedyan S Horm Cancer; 2017 Feb; 8(1):28-48. PubMed ID: 28050800 [TBL] [Abstract][Full Text] [Related]
5. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102 [TBL] [Abstract][Full Text] [Related]
7. Abnormal expression of the ERG transcription factor in prostate cancer cells activates osteopontin. Flajollet S; Tian TV; Flourens A; Tomavo N; Villers A; Bonnelye E; Aubert S; Leroy X; Duterque-Coquillaud M Mol Cancer Res; 2011 Jul; 9(7):914-24. PubMed ID: 21669963 [TBL] [Abstract][Full Text] [Related]
8. Expression of steroid and peptide hormone receptors, metabolic enzymes and EMT-related genes in prostate tumors in relation to the presence of the TMPRSS2/ERG fusion. Gerashchenko GV; Mevs LV; Chashchina LI; Pikul MV; Gryzodub OP; Stakhovsky EO; Kashuba VI Exp Oncol; 2018 Jun; 40(2):101-108. PubMed ID: 29949537 [TBL] [Abstract][Full Text] [Related]
9. An NKX3.1 binding site polymorphism in the l-plastin promoter leads to differential gene expression in human prostate cancer. Chen C; Cai Q; He W; Li Z; Zhou F; Liu Z; Zhong G; Chen X; Zhao Y; Dong W; Huang J; Zheng J; Lin T Int J Cancer; 2016 Jan; 138(1):74-86. PubMed ID: 26148677 [TBL] [Abstract][Full Text] [Related]
10. Role of TMPRSS2-ERG gene fusion in negative regulation of PSMA expression. Yin L; Rao P; Elson P; Wang J; Ittmann M; Heston WD PLoS One; 2011; 6(6):e21319. PubMed ID: 21731703 [TBL] [Abstract][Full Text] [Related]
11. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. Setlur SR; Mertz KD; Hoshida Y; Demichelis F; Lupien M; Perner S; Sboner A; Pawitan Y; Andrén O; Johnson LA; Tang J; Adami HO; Calza S; Chinnaiyan AM; Rhodes D; Tomlins S; Fall K; Mucci LA; Kantoff PW; Stampfer MJ; Andersson SO; Varenhorst E; Johansson JE; Brown M; Golub TR; Rubin MA J Natl Cancer Inst; 2008 Jun; 100(11):815-25. PubMed ID: 18505969 [TBL] [Abstract][Full Text] [Related]
12. Transcriptional regulation of CXCR4 in prostate cancer: significance of TMPRSS2-ERG fusions. Singareddy R; Semaan L; Conley-Lacomb MK; St John J; Powell K; Iyer M; Smith D; Heilbrun LK; Shi D; Sakr W; Cher ML; Chinni SR Mol Cancer Res; 2013 Nov; 11(11):1349-61. PubMed ID: 23918819 [TBL] [Abstract][Full Text] [Related]
13. TMPRSS2-ERG fusion protein regulates insulin-like growth factor-1 receptor (IGF1R) gene expression in prostate cancer: involvement of transcription factor Sp1. Meisel Sharon S; Pozniak Y; Geiger T; Werner H Oncotarget; 2016 Aug; 7(32):51375-51392. PubMed ID: 27285981 [TBL] [Abstract][Full Text] [Related]
14. Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis. Sandoval GJ; Pulice JL; Pakula H; Schenone M; Takeda DY; Pop M; Boulay G; Williamson KE; McBride MJ; Pan J; St Pierre R; Hartman E; Garraway LA; Carr SA; Rivera MN; Li Z; Ronco L; Hahn WC; Kadoch C Mol Cell; 2018 Aug; 71(4):554-566.e7. PubMed ID: 30078722 [TBL] [Abstract][Full Text] [Related]
15. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Tu JJ; Rohan S; Kao J; Kitabayashi N; Mathew S; Chen YT Mod Pathol; 2007 Sep; 20(9):921-8. PubMed ID: 17632455 [TBL] [Abstract][Full Text] [Related]
16. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer. Winnes M; Lissbrant E; Damber JE; Stenman G Oncol Rep; 2007 May; 17(5):1033-6. PubMed ID: 17390040 [TBL] [Abstract][Full Text] [Related]
17. TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer. Swanson TA; Krueger SA; Galoforo S; Thibodeau BJ; Martinez AA; Wilson GD; Marples B Prostate; 2011 Oct; 71(14):1548-58. PubMed ID: 21394739 [TBL] [Abstract][Full Text] [Related]
18. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Pflueger D; Rickman DS; Sboner A; Perner S; LaFargue CJ; Svensson MA; Moss BJ; Kitabayashi N; Pan Y; de la Taille A; Kuefer R; Tewari AK; Demichelis F; Chee MS; Gerstein MB; Rubin MA Neoplasia; 2009 Aug; 11(8):804-11. PubMed ID: 19649210 [TBL] [Abstract][Full Text] [Related]
19. Characterization of two functional NKX3.1 binding sites upstream of the PCAN1 gene that are involved in the positive regulation of PCAN1 gene transcription. Liu W; Zhang P; Chen W; Yu C; Cui F; Kong F; Zhang J; Jiang A BMC Mol Biol; 2008 May; 9():45. PubMed ID: 18454873 [TBL] [Abstract][Full Text] [Related]
20. TMPRSS2:ERG gene fusion expression regulates bone markers and enhances the osteoblastic phenotype of prostate cancer bone metastases. Delliaux C; Tian TV; Bouchet M; Fradet A; Vanpouille N; Flourens A; Deplus R; Villers A; Leroy X; Clézardin P; de Launoit Y; Bonnelye E; Duterque-Coquillaud M Cancer Lett; 2018 Dec; 438():32-43. PubMed ID: 30201302 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]